TW202408500A - 血中ｌｄｌ膽固醇降低劑 - Google Patents

血中ｌｄｌ膽固醇降低劑 Download PDF

Info

Publication number
TW202408500A
TW202408500A TW112126331A TW112126331A TW202408500A TW 202408500 A TW202408500 A TW 202408500A TW 112126331 A TW112126331 A TW 112126331A TW 112126331 A TW112126331 A TW 112126331A TW 202408500 A TW202408500 A TW 202408500A
Authority
TW
Taiwan
Prior art keywords
blood
ldl
statins
administration
blood ldl
Prior art date
Application number
TW112126331A
Other languages
English (en)
Chinese (zh)
Inventor
谷川亮平
Original Assignee
日商興和股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商興和股份有限公司 filed Critical 日商興和股份有限公司
Publication of TW202408500A publication Critical patent/TW202408500A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112126331A 2022-07-15 2023-07-14 血中ｌｄｌ膽固醇降低劑 TW202408500A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-113930 2022-07-15
JP2022113930 2022-07-15

Publications (1)

Publication Number Publication Date
TW202408500A true TW202408500A (zh) 2024-03-01

Family

ID=89536850

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112126331A TW202408500A (zh) 2022-07-15 2023-07-14 血中ｌｄｌ膽固醇降低劑

Country Status (8)

Country Link
US (1) US20260014122A1 (https=)
EP (1) EP4556006A4 (https=)
JP (1) JPWO2024014524A1 (https=)
KR (1) KR20250034041A (https=)
CN (1) CN119546300A (https=)
JO (1) JOP20250007A1 (https=)
TW (1) TW202408500A (https=)
WO (1) WO2024014524A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009374B1 (ru) 2003-09-03 2007-12-28 Кова Ко., Лтд. Активирующее ppar соединение и содержащая его фармацевтическая композиция
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
DK3275438T3 (da) * 2016-07-29 2021-01-18 Kowa Co Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko
JP2021506907A (ja) * 2017-12-21 2021-02-22 興和株式会社 高トリグリセライド血症の治療方法
US11446282B2 (en) * 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
US20240277745A1 (en) * 2021-05-27 2024-08-22 Kowa Company, Ltd Pemafibrate and/or tofogliflozin for use in treating liver disease

Also Published As

Publication number Publication date
WO2024014524A1 (ja) 2024-01-18
KR20250034041A (ko) 2025-03-10
JOP20250007A1 (ar) 2025-01-13
EP4556006A4 (en) 2026-01-07
CN119546300A (zh) 2025-02-28
EP4556006A1 (en) 2025-05-21
US20260014122A1 (en) 2026-01-15
JPWO2024014524A1 (https=) 2024-01-18

Similar Documents

Publication Publication Date Title
US10632112B2 (en) Combination therapy for treatment of HBV infections
EP1353696B1 (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
JP2024530310A (ja) Ｔ細胞リンパ腫治療薬の調製におけるｅｚｈ２阻害剤の使用
US12042483B2 (en) Prophylactic and therapeutic drug for nonalcoholic fatty liver disease
US20180078518A1 (en) Fixed Dose Combinations and Formulations Comprising ETC1002 and One or More Statins and Methods of Treating or Reducing Cardiovascular Disease
WO2003082338A1 (en) Remedies for glomerular diseases
TW202408500A (zh) 血中ｌｄｌ膽固醇降低劑
Baetz et al. A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours
US20210322376A1 (en) Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses
JP6454436B1 (ja) ペマフィブラートを含有する医薬
WO2001034134A2 (en) Oncolytic combinations for the treatment of cancer
CN112451678B (zh) HMG-CoA还原酶抑制剂-维D的药物组合物及用途
WO2022224962A1 (ja) 脂質異常症又は心臓血管病の予防・治療のための組合せ医薬
CN101411697A (zh) 一种治疗心血管疾病的药物组合物
TW202408499A (zh) 降低血中肌肉生長抑制素之藥劑
KR20240168338A (ko) 호흡기 질환 치료제
US10576101B2 (en) Roneparstat combined therapy of multiple myeloma
CN101534825A (zh) 含有贝特类药物的制剂及其制备方法
JP2005533851A (ja) 高コレステロール血症処置用物質および方法
OA20813A (en) Methods of administering voxelotor
WO2006090756A1 (ja) 脂質代謝異常、肥満および糖尿病の新規な予防または治療剤およびそのための使用
US20050234124A1 (en) Carboxyalkylether-ACAT inhibitor combinations
JP2007308484A (ja) 高脂血症の予防及び／又は治療のための医薬
HK1056696B (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications